Evidence map›Paper›PMID 33520873›Full record

ReviewJournal of diabetes and metabolic disorders2020

Association of plasminogen activator inhibitor-1 4G5G Polymorphism with risk of diabetic nephropathy and retinopathy: a systematic review and meta-analysis.

Seyed Alireza Dastgheib, Farzaneh Najafi, Ahmad Shajari, Reza Bahrami, Fatemeh Asadian, Jalal Sadeghizadeh-Yazdi, Elahe Akbarian, Seyed Alireza Emarati, Hossein Neamatzadeh

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of diabetes and metabolic disorders, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Seyed Alireza DastgheibDepartment of Medical Genetics, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Farzaneh NajafiDepartment of Internal Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Ahmad ShajariDepartment of Pediatrics, Yazd Branch, Islamic Azad University, Yazd, Iran.
Reza BahramiNeonatal Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Fatemeh AsadianDepartment of Medical Laboratory Sciences, School of Paramedical Science, Shiraz University of Medical Sciences, Shiraz, Iran.
Jalal Sadeghizadeh-YazdiDepartment of Food Science and Technology, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Elahe AkbarianChildren Growth Disorder Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Seyed Alireza EmaratiChildren Growth Disorder Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Hossein NeamatzadehDepartment of Medical Genetics, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe 4G5G polymorphism of Plasminogen activator inhibitor-1 (PAI-1) gene is reported to be associated with diabetes nephropathy and retinopathy (DNR) risk. However, the findings are conflicting. Herein, we conducted a case-control and meta-analysis study to explore the association of PAI-1 4G5G polymorphism with risk of DNR.

methodsWe retrieved PubMed, EMBASE, Web of Knowledge, and CNKI databases and screened eligible studies up to August 15, 2020. The strength of associations was assessed by odd ratio (OR) and the corresponding 95% confidence interval (95% CI).

resultsA total of 27 case-control studies including 16 studies with 1,825 cases case and 1,731 controls on DN and eleven studies with 1,397 cases and 1,545 controls on DR were selected. Pooled data showed that the PAI-1 4G5G polymorphism was significantly associated with DN (allele model: OR = 0.674, 95% CI 0.524-0.865, p = 0.002; homozygote model: OR = 0.536, 95% CI 0.351-0.817, p = 0.004; heterozygote model: OR = 0.621, 95% CI 0.427-0.903, p = 0.013; dominant model: OR = 0.575, 95% CI 0.399-0.831, p = 0.003; and recessive model: OR = 0.711, 95% CI 0.515-0.981, p = 0.038) and DR (homozygote model: OR = 0.770, 95% CI 0.621-0.955, p = 0.0.017) risk. Stratified analyses by ethnicity indicated that PAI-1 4G5G polymorphism was associated with DN and DR risk in Asians and Caucasians, respectively.

conclusionsThe present meta-analysis revealed that the PAI-1 4G5G polymorphism was associated with increased risk of DN and DR risk. However, well-designed large-scale clinical studies are required to further validate our results.

Indexed as

Diabetic MellitusMeta-AnalysisNephropathyPAI-1 GeneRetinopathy

Identifiers

PMID33520873
PMCPMC7843759

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.